预约演示
更新于：2026-08-29
Icodextrin
艾考糊精
更新于：2026-08-29
概要
基本信息
权益机构- |
最高研发阶段批准上市 |
首次获批日期 美国 (2002-12-20), |
最高研发阶段(中国)临床3期 |
特殊审评- |
登录后查看时间轴
关联
40
项与 艾考糊精 相关的临床试验ChiCTR2600129249
Evaluation of the equivalence in safety and efficacy of Aikao icodextrin peritoneal dialysis solution for long dwell peritoneal dialysis once daily in non-bedridden patients with end-stage renal disease: a multicenter, randomized, open-label, reference formulation-controlled clinical trial
ACTRN12625001314415
A Randomized Controlled Trial Comparing 4% Icodextrin Adhesion-Reduction Solution With No Intervention on Post-Surgical Ovarian Adhesion Formation in Patients With Fixed or Immobile Ovaries: A Transvaginal Ultrasound-Based Assessment
NCT07168343
The Effect of Two Icodextrin Exchanges on Fluid Status and Blood Pressure Control in Children on Chronic Peritoneal Dialysis
100 项与 艾考糊精 相关的临床结果
登录后查看更多信息
100 项与 艾考糊精 相关的转化医学
登录后查看更多信息
100 项与 艾考糊精 相关的专利（医药）
登录后查看更多信息
488
项与 艾考糊精 相关的文献（医药）2026-07-01PERITONEAL DIALYSIS INTERNATIONAL
Icodextrin lowers serum sodium in dose-dependent fashion: A case report
Article
作者: Karakadze, Marko ; Sugar, Sophia ; Teitelbaum, Isaac
Icodextrin (ICO) is widely used in peritoneal dialysis (PD). Hyperosmolar hyponatremia (hypoNa) has been reported as an adverse event of ICO, but it is unknown whether there is a dose effect relationship between the two. We present a case demonstrating this relationship. A 61-year-old woman with end-stage kidney disease (ESKD) and no history of diabetes, began PD with a single daily dwell of 1L of ICO. Her serum Na during the previous 6 months (n = 16) was 138.9 (mmol/L) ± 2.2 (SD). Within days of starting PD, the Na fell to 132 and over the ensuing 9 months (n = 27) it averaged 133.6 ± 2.1. As her PD prescription (Rx) was changed throughout two hospital admissions and subsequent outpatient management, she maintained normonatremia when using dextrose exchanges and became hyponatremic with ICO exchanges. With increasing daily doses of ICO, her hyponatremia became more severe (nadir of Na 121 with 3L of daily ICO use). She ultimately returned to exclusively dextrose cycles for two years and remained normonatremic. Years later a single 2L ICO dwell was started, and she developed hypoNa again (Na 131). ICO was stopped and Na normalized. We plotted serum Na vs total daily ICO dose and showed a strong correlation (R
2
= 0.737). HypoNa is a risk factor for ESKD patients that lead to increased morbidity and mortality. This report demonstrates that the severity of ICO-induced hyponatremia is directly proportional to the amount of ICO used. For patients developing hyponatremia, instead of discontinuing ICO, practitioners might consider reducing the dose.
2026-07-01PERITONEAL DIALYSIS INTERNATIONAL
Response to “Icodextrin lowers serum sodium in dose-dependent fashion: A case report” : Keep calm and continue Icodextrin
Letter
2026-07-01PERITONEAL DIALYSIS INTERNATIONAL
Estimating the costs and amount of recyclable polyvinyl chloride plastic waste associated with discarded Icodextrin
Article
作者: Ghimire, Anukul ; Quinn, Robert R. ; Vitale, George ; Kahlon, Bhavneet ; Shah, Meera ; Ward, David ; Qirjazi, Elena ; Tennankore, Karthik K. ; Shah, Nikhil
There is limited data characterizing healthcare waste associated with peritoneal dialysis (PD). In Canada, Icodextrin for continuous cycling PD (CCPD) is only available as 2.5L bags for one-time use, and any remaining volume that is not used for a dwell is discarded. The environmental impact of this practice has not been well characterized. As such, we sought to estimate the costs associated with discarded Icodextrin and associated polyvinyl chloride (PVC) plastic waste production within our renal program. We conducted a cross-sectional audit of all patients utilizing CCPD in the Alberta Kidney Care South program in Canada in 2022. Icodextrin fill volume data were captured and the costs associated with Icodextrin use were calculated. Among patients on CCPD, the average fill volume for Icodextrin was 1273 mL, suggesting that an average of 1227 mL was discarded. In fact, 88% of patients used dwell volumes ≤1.5L. In 2021, our program spent $1.27 million CAD on Icodextrin for CCPD. Given that an average of 49% of each 2.5L bag was discarded, we estimate that the annual value of wasted Icodextrin among patients being treated with CCPD in our program was $622,300 CAD, or $3036 CAD per patient. Annual PVC waste was calculated to be 25.9 kg per patient, and we estimate that PVC waste could be reduced by 35% if there was access to 1.5L Icodextrin solutions. Our work suggests that the availability of Icodextrin bags that are better aligned with volumes used by patients could reduce healthcare costs and PVC waste.
100 项与 艾考糊精 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 肾脏疾病 | 日本 | - | 2003-11-29 |
| 终末期肾脏病 | 美国 | 2002-12-20 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 心脏衰竭 | 临床2期 | 美国 | 2006-08-01 | |
| 心脏衰竭 | 临床2期 | 澳大利亚 | 2006-08-01 | |
| 心脏衰竭 | 临床2期 | 比利时 | 2006-08-01 | |
| 心脏衰竭 | 临床2期 | 加拿大 | 2006-08-01 | |
| 高甘油三酯血症 | 临床阶段不明 | 韩国 | - |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | - | 83 | Two icodextrin + one glucose | 鏇襯窪衊窪廠憲壓選繭(齋糧遞觸觸繭鏇繭積膚) = 鹽繭鏇淵壓窪願夢憲廠 鏇鑰構構壓鹹鹽齋餘鬱 (繭餘艱鬱衊衊廠鑰膚艱 ) 更多 | 积极 | 2024-10-24 | |
One icodextrin + two glucose | 鏇襯窪衊窪廠憲壓選繭(齋糧遞觸觸繭鏇繭積膚) = 繭餘顧醖蓋鏇壓繭襯願 鏇鑰構構壓鹹鹽齋餘鬱 (繭餘艱鬱衊衊廠鑰膚艱 ) 更多 | ||||||
N/A | - | 43 | 鏇鑰鹹蓋蓋醖築網壓遞(膚構鏇鑰鹹淵鬱襯蓋齋) = 繭夢窪淵壓廠鏇艱簾憲 鑰鑰膚艱構網獵鏇鏇鏇 (簾獵積遞餘齋壓齋製願 ) | - | 2018-05-08 | ||
Glucose-based solution | 選膚廠繭糧獵窪糧衊蓋(顧願齋獵製鏇鹹鹽窪鏇) = 鑰鬱鏇鹹製壓鑰齋廠鏇 糧鏇窪選蓋艱夢製願淵 (願餘獵選襯鹹繭觸簾獵 ) 更多 | ||||||
N/A | 300 | (Standard surgery) | 遞鹹醖鑰構糧憲蓋網繭(齋廠窪構鏇觸醖艱鬱遞) = 襯鹽繭窪顧築鹹壓簾夢 膚製鑰顧襯鏇夢廠範淵 (遞網淵膚觸淵製築壓憲 ) | - | 2016-03-01 | ||
Standard surgery with icodextrin instillation | 遞鹹醖鑰構糧憲蓋網繭(齋廠窪構鏇觸醖艱鬱遞) = 鹹餘獵襯築製範製積壓 膚製鑰顧襯鏇夢廠範淵 (遞網淵膚觸淵製築壓憲 ) | ||||||
临床4期 | 53 | 淵築鬱蓋繭衊願範鏇艱(顧範積膚選製製範衊壓) = 夢廠憲蓋獵齋夢築獵廠 餘繭願製遞淵齋齋憲醖 (醖衊廠蓋壓遞襯遞顧餘 ) 更多 | - | 2014-07-01 | |||
Original glucose-based dialysis solution | 淵築鬱蓋繭衊願範鏇艱(顧範積膚選製製範衊壓) = 繭艱網繭鏇鏇壓製鑰齋 餘繭願製遞淵齋齋憲醖 (醖衊廠蓋壓遞襯遞顧餘 ) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
提出任何生物医药研究问题
让每一步生物医药决策都精准制胜
基于十亿级生物数据与全球情报的精准 AI，赋能早期药物发现
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即接入生物医药数据包
智慧芽新药库数据也通过智慧芽开放平台，以MCP或API服务形式对外开放。立即使用我们的MCP服务定制您的LLM智能体。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用